A Randomized, Open Label, Two-part, Three-period, Cross Over Study to Investigate the Effects of Carbohydrate in Diet and to Evaluate Supplements on the Gastrointestinal Tolerability of LIK066 in Overweight or Obese Subjects
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2018
At a glance
- Drugs LIK 066 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 27 Oct 2017 Status changed from recruiting to completed.
- 09 Aug 2017 Status changed from not yet recruiting to recruiting.
- 28 Jun 2017 New trial record